ArticleCurrent infectious disease reports2008
Invasive candidiasis in the ICU: prophylaxis versus preemptive treatment.
Article in Current infectious disease reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidemia/invasive candidiasis has increased in incidence over the past 15 years. Because of numerous risk factors, intensive care unit patients have a predilection for this type of infection. Most of these infections are acquired endogenously, but occasionally may result from an exogenous source. Antifungal prophylaxis and preemptive antifungal therapy have been developed to prevent candidemia/invasive candidiasis. Antifungal prophylaxis with azoles has been demonstrated to reduce candidemia, overall mortality, and attributable mortality. This strategy is also effective for the prevention of invasive fungal infection in liver transplant recipients. Preemptive treatment appears to be a more focused intervention that uses markers (eg, the presence of colonization) and serologic testing to trigger the initiation of antifungal therapy. Further developments in serologic testing are necessary to enhance the precision of selecting the patients at risk for candidemia/invasive candidiasis. The optimum agent to be used prophylactically and for preemptive therapy requires further clinical investigation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.